-

10:17:05 PM

ADOCY Stock News

ADOCY - Adocia

06/23/22 12:30 PM

OTC : ADOCY

low float

Adocia Publishes its Letter to Shareholders

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the Letter to Shareholders for the 1st semester of 2022.. Adocia is a biotechnology company specializing in the discovery and...

RHEA-AI

neutral

06/21/22 12:00 PM

OTC : ADOCY

clinical triallow float

ADOCIA Announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today positive top-line results in a Phase 2 trial comparing M1Pram to Humalog in people with Type 1 Diabetes. “We are really pleased to confirm that M1Pram...

RHEA-AI

neutral

06/16/22 12:00 PM

OTC : ADOCY

low float

ADOCIA confirms its eligibility for the PEA–PME

Adocia, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic solutions for the treatment of diabetes and other metabolic diseases, confirms its eligibility for the“ PEA– PME” stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014, and which entered into force on...

RHEA-AI

neutral

06/14/22 12:00 PM

OTC : ADOCY

low float

Number of shares and voting rights of ADOCIA as of May 31st, 2022

Pursuant to the provisions of article L. 233-8 II of the French« Code de Commerce » and article 223-16 of the French stock-market authorities charter ADOCIA SA, a French société anonyme, 115, avenue Lacassagne, 69003 Lyon, a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative...

RHEA-AI

neutral

05/20/22 12:00 PM

OTC : ADOCY

low float

ADOCIA Announces its Annual Shareholders’ Meeting to Be Held on June 28, 2022 in Paris

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting on June 28, 2022, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin,...

RHEA-AI

neutral

05/18/22 12:00 PM

OTC : ADOCY

earningslow float

ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports today its first quarter financial results for 2022 and provides corporate update. The Company’ s revenue primarily stems from the licensing and...

RHEA-AI

positive

05/18/22 3:00 AM

OTC : ADOCY

partnershipclinical triallow float

ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the first subject treated in the BioChaperone ® Combo CT046 clinical study. CT046 is one of the three clinical studies– together with CT047 and CT048-...

RHEA-AI

neutral

05/13/22 12:00 PM

OTC : ADOCY

low float

Number of Shares and Voting Rights of ADOCIA as of April 30th, 2022

Pursuant to the provisions of article L. 233-8 II of the French« Code de Commerce » and article 223-16 of the French stock-market authorities charter ADOCIA SA, a French société anonyme, 115, avenue Lacassagne, 69003 Lyon, a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative...

RHEA-AI

neutral

05/09/22 3:00 AM

OTC : ADOCY

partnershipclinical triallow float

ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the dosing of the first patient with the BioChaperone ® Lispro Phase 3 study. “We are proud to be one of the very few companies bringing an innovative...

RHEA-AI

neutral

04/25/22 12:00 PM

OTC : ADOCY

low float

ADOCIA Announces the Release of its Universal Registration Document for the Year 2021

Adocia, a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the filing of its 2021 Universal Reference Document with the“ Autorité des marchés financiers” on April 21, 2020. Adocia is a biotechnology company...

RHEA-AI

neutral